Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Growth Phase

Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Growth Phase

H2 Global Group, together with its subsidiary H2 Medical Technologies, has entered a decisive growth stage following strong recognition at LSI Europe 2025 in London. The group presented its breakthrough approach to preventing and treating neurodegenerative diseases, including Alzheimer’s, confirming its position among global leaders in the MedTech and HealthTech sectors.

At the core of this innovation is a prototype medical device for controlled hydrogen therapy, developed by H2 Medical Technologies. The device is designed for patients with mild cognitive impairment, a condition that often precedes Alzheimer’s. Non-invasive and suitable for both clinical and home use, it is based on a patented method pioneered by a Japanese team led by Professor Shigeo Ohta, co-owner of H2 Global Group. Research indicates that molecular hydrogen can protect brain cells, slow inflammation, and support neuronal metabolism and connectivity.

“Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence,” explains Prof. Ohta.

Group founder David Maršálek, who has been developing hydrogen technologies since 2011, adds: “Our mission is to launch the world’s first hydrogen-based medical device for Alzheimer’s prevention and therapy support. With strong scientific evidence, patent protection, and an experienced team, we are positioned to succeed.”

Between 2021 and 2025, H2 Global Group raised over $18M in Seed funding, built a network of 20,000 end-customers and 50+ B2B partners, and exceeded revenues of circa $7.4M. Current transactions value the group at circa $77M.

Now entering Series A, the group plans to raise $25–30 million to fund global expansion into Europe, the U.S., the Middle East, and Africa, complete clinical trials, and secure EU and FDA registrations. Revenue projections forecast growth to nearly $48M by 2029.

The portfolio extends beyond the medical device. H2 Medical Technologies supplies hydrogen generators and therapeutic systems to spas, sports clubs, physiotherapy practices or dental clinics. Its solutions are also approved for veterinary use. In parallel, H2 Pharm develops consumer products such as H2 Premium Water®, H2 Brain®, H2 Forte®, and H2 Dent Care®, which are commercially successful and distributed via e-commerce and a B2B network.

“Such opportunities are rare,” concludes Maršálek. “When future textbooks are written, our investors will say: I was there. Hydrogen is not only energy source but a molecule of lifeconnecting the world. Invest in Hydrogen!”

Source: ap.news.com

Czech MedTech Startup H2 Medical Technologies Unveils World’s First Patented Hydrogen-Based Therapy with the Potential to Target Alzheimer’s Disease

Czech MedTech Startup H2 Medical Technologies Unveils World’s First Patented Hydrogen-Based Therapy with the Potential to Target Alzheimer’s Disease

H2 Medical Technologies, part of the H2 Global Group, has developed the world’s first functional hydrogen-based therapy medical device prototype for clinical trials — aimed at both preventing and treating Alzheimer’s disease.

Today, more than 6.5 million Americans and 50 million people worldwide are living with Alzheimer’s and other forms of dementia. According to the World Health Organization, this number could triple by 2050, placing an immense burden on families and healthcare systems. Despite decades of research, no effective solution has been found — until now.

“This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer’s disease before it even starts, while supporting those already affected,” says David Marsalek, founder and CEO of H2 Global Group. The company believes its effectiveness will be further confirmed in an upcoming new clinical trial. “Our mission is clear: to turn decades of research into real hope for millions of families around the world. We are part of a strong vision of a society where hydrogen is the molecule of life that connects the world.”

From the Lab to the Global Stage

H2 Global Group will present this breakthrough at LSI Europe 2025 in London, one of the world’s most prestigious MedTech and HealthTech conferences. The project builds on 30+ years of research and patents developed with Professor Shigeo Ohta, a global leader in molecular hydrogen science and co-founder of H2 Global Group.

More Than Medicine: A New Era of Brain Health

While the immediate focus is Alzheimer’s, potential applications extend to neurological disorders, brain regeneration, and healthy aging.

Alongside its medical device, H2 Global Group has launched consumer products such as H2 Premium Water® and H2 Brain®, a world-first two-phase dietary supplement that stimulates molecular hydrogen production through the gut microbiome. The company is also the only certified global manufacturer authorized to use hydrogen-based medical devices in veterinary medicine.

Today, its hydrogen-based solutions are already being adopted by wellness centers, rehabilitation clinics, dental practices, and elite sports organizations across Europe — underscoring the broad potential of the technology.

An Opportunity for Visionary Investors

Until now, the project has been funded primarily by Czech investors. H2 Global Group is now opening the door to U.S. and global partners at a critical growth stage, with EU registration underway and FDA approval next on the horizon — unlocking the world’s largest healthcare market.

The global Alzheimer’s therapeutics market is projected to exceed $20 billion by 2030, with dementia-related costs already surpassing $1 trillion annually. Positioned as the only functional hydrogen-based therapy of its kind, H2 Global Group offers investors a rare first-mover advantage in one of the most urgent and lucrative markets of our time.

H2 Brain®: Innovative Support for Mental Well-being at the Cellular Level

H2 Brain®: Innovative Support for Mental Well-being at the Cellular Level

H2 Vibe proudly introduces H2 Brain®, an innovative food supplement developed to support mental wellbeing and cognitive performance – both during the day and at night. This unique two-phase formulation respects the body’s natural circadian rhythm and is carefully tailored to meet the brain’s changing needs throughout the day.

Today’s fast-paced lifestyle, combined with a lack of physical activity and chronic stress, is taking a toll on our mental health. “People today live under immense pressure, which often results in poor sleep quality and a general sense of mental unease,” explains Viktória Procházková, CEO of H2 Global Group. “At the same time, data indicates a growing prevalence of neurological disorders, which motivated us to develop a comprehensive solution aimed at supporting cognitive function and emotional balance.”

For nearly a year, the Czech company H2 Global Group fine-tuned the formula to perfection – resulting in H2 Brain®, a two-phase supplement designed to meet the brain’s essential needs and promote mental clarity and emotional resilience. “Throughout the development of H2 Brain®, we paid close attention to the bioavailability and synergistic interactions of each ingredient to achieve maximum efficacy at the cellular level,” adds PharmDr. Milan Krajíček, Head of Research and Production at H2 Pharm.

Targeted Support – Day and Night

H2 Brain® has been developed as a two-phase system to address the brain’s distinct daytime and nighttime needs. The morning tablet is focused on enhancing concentration and cognitive performance throughout the day. It includes Baikal skullcap extract, astaxanthin, and selenium with sustained release properties. The evening tablet, by contrast, is formulated to encourage mental relaxation and restorative sleep, with ingredients such as taurine, B vitamins, and ginkgo biloba.

H2 Brain® also features the patented HydrogenIQ complex, which naturally supports the production of molecular hydrogen. As the smallest molecule in the universe, molecular hydrogen is currently being explored for its unique ability to cross the blood–brain barrier and reach brain cells. Research suggests it may play a beneficial role in promoting cellular regeneration and protecting neurons against oxidative stress.

For Students, Professionals, Parents and Seniors

H2 Brain® is designed for a wide range of individuals – from students seeking to boost focus during intensive study, to professionals and parents managing high cognitive loads, to older adults looking to support mental clarity and cognitive longevity. “Our aim with H2 Brain® was to create a supplement that actively supports brain function and contributes to long-term mental wellbeing,” concludes Krajíček.

According to the World Health Organization (WHO), approximately 55 million people worldwide are currently living with dementia, with around 10 million new cases diagnosed each year. Alzheimer’s disease accounts for 60–70% of these cases. By 2050, the global number of people affected by dementia is expected to rise to 139 million. This alarming trend highlights the urgent need for proactive measures to support brain health from midlife onwards.

Molecular hydrogen and oxidative stress reduction

Molecular hydrogen and oxidative stress reduction

Imagine oxidative stress as an invisible enemy silently damaging your body. Free radicals attack your cells, while your natural antioxidants struggle to keep up. This internal chaos can lead to serious conditions such as heart disease, cancer, and accelerated ageing. Fortunately, molecular hydrogen (H₂) offers a solution—acting as a selective antioxidant that targets the most harmful free radicals and supports health at the cellular level.

Molecular Hydrogen as a Selective Antioxidant

Molecular hydrogen is unique in its ability to selectively neutralise the most dangerous free radicals, such as the hydroxyl radical (•OH), without interfering with beneficial oxidative processes that are essential to the body’s function. This selective action makes molecular hydrogen a powerful ally in combating oxidative stress without disrupting normal cellular activity.

Groundbreaking Research by Professor Shigeo Ohta

The first major scientific study to highlight the potential of molecular hydrogen in medicine was published in 2007 by Japanese biochemist Professor Shigeo Ohta in the prestigious journal Nature Medicine. The study showed that inhaling molecular hydrogen significantly reduced oxidative stress-induced cellular damage in animal models. This landmark discovery sparked widespread scientific interest in the therapeutic potential of molecular hydrogen.

Further Studies and Clinical Evidence

Since Professor Ohta’s publication, numerous studies have confirmed the efficacy of molecular hydrogen in reducing oxidative stress. For example, research published in the Journal of Clinical Biochemistry and Nutrition demonstrated that drinking hydrogen-rich water reduced markers of oxidative stress in patients with metabolic syndrome.

Another study, published in the Journal of Neurochemistry, found that molecular hydrogen could protect brain cells from oxidative damage and inflammation—suggesting its potential in preventing and treating neurodegenerative diseases such as Alzheimer’s disease.

Clinical trials have also shown benefits for patients with rheumatoid arthritis, coronary artery disease, and even for athletes exposed to high levels of oxidative stress due to intense physical activity.

Image: Molecular hydrogen shows promise in the treatment and prevention of Alzheimer’s and other neurodegenerative conditions.
Photo credit: Shutterstock

Mechanisms of Action

Molecular hydrogen acts not only as a selective antioxidant, but also as a signalling molecule that influences various biochemical pathways in the body. For instance, it activates the Nrf2 pathway, which regulates the expression of antioxidant enzymes and enhances the body’s natural defences against oxidative stress. Moreover, molecular hydrogen is believed to modulate inflammatory responses, which is significant in the treatment of chronic inflammatory diseases.

A Promising Step Towards Better Health

Molecular hydrogen is emerging as a highly promising tool for reducing oxidative stress and protecting cells from associated damage. Backed by scientific and clinical research, its use is increasingly gaining recognition not only among medical professionals but also the wider public. While further studies are still needed, existing evidence suggests that molecular hydrogen could play a vital role in the prevention and treatment of a wide range of conditions linked to oxidative stress.

Header image source: Shutterstock

World news: Czech patent – Hydrogen virtual reality

World news: Czech patent – Hydrogen virtual reality

A World First: H₂ Global Group Combines Molecular Hydrogen and Virtual Reality for Groundbreaking Therapy

The Ostrava-based company H₂ Global Group is introducing a pioneering innovation that unites the regenerative power of Molecular Hydrogen® with the immersive capabilities of virtual reality.

“The principle is surprisingly simple,” explains David Maršálek, President of H₂ Global Group. “Inhaling molecular hydrogen amplifies the effects of brain-focused therapies conducted within a virtual environment.” This cutting-edge development, now registered as a Czech patent, opens a new chapter in the field of integrative health technology.

Virtual Scenarios That Heal

During therapy, patients are immersed in realistic virtual situations to which the brain responds as if they were real. This immersive experience enhances rehabilitation, helps reduce anxiety and psychological disorders, and can even boost cognitive performance. “The addition of molecular hydrogen significantly intensifies the therapeutic effect,” adds Maršálek.

While virtual reality (VR) is widely associated with gaming or simulated adventures, it has become a vital tool in modern healthcare. The integration of VR with hydrogen inhalation is a global first. As the hydrogen gas enters the bloodstream via the lungs, it is distributed throughout the body—combining with movement to create a powerful therapy suitable for various medical disciplines.

“When immersed in the virtual world, a person focuses entirely on the experience, distancing themselves from external stimuli and entering a space that actively supports healing,” explains VR specialist Dr Jana Trdá.

A World Patent: Virtual Reality Meets Molecular Hydrogen

“Numerous Czech and international studies have confirmed hydrogen’s ability to restore cellular balance disrupted by oxidative stress. It effectively neutralises harmful free radicals,” says David Maršálek.

“The combination of medical expertise, cutting-edge technology, and molecular hydrogen benefits both patients and practitioners. We’ve applied for a Czech patent for this unique therapeutic approach, which we plan to expand globally.”

In collaboration with H₂ Medical Technologies, VR Life has developed a module focused specifically on hydrogen inhalation, compatible with their hydrogen inhalators and generators.

“Studies have shown hydrogen’s positive impact on performance, endurance, and post-exercise recovery,” adds Professor Shigeo Ohta, Vice President for Science and Research at H₂ Global Group. “Inhaled hydrogen from our generators also accelerates regeneration, for example after post-COVID fatigue, and is effective against numerous conditions due to its anti-inflammatory properties. It has shown promising results in patients with Alzheimer’s disease. The combination of hydrogen and VR is certain to bring extraordinary results.”

A Victorian Greenhouse or a Hydrogen-Powered Tent?

Hydrogen VR therapy can be conducted sitting or standing. At the request of H₂ Medical, VR Life designed a bespoke environment in the form of a virtual Victorian greenhouse filled with flowers and soothing nature sounds, simulating warm, humid air.

“The patient sees animated lungs expanding and contracting with each breath, encouraging coordinated breathing and effective inhalation of hydrogen,” says Dr Trdá. Seated patients use nasal cannulas for hydrogen inhalation while immersed in this calming visual experience.

“For standing exercises, we developed a hydrogen tent that is enclosed and filled with hydrogen-enriched air, allowing users to move freely during VR therapy,” she explains.

Gamified Healing

A major strength of VR therapy lies in its gamification elements. “We apply game-like mechanics to motivate patients during rehabilitation,” explains Dr Trdá.

Each exercise is designed and validated by a team of doctors, physiotherapists and occupational therapists, ensuring both effectiveness and medical accuracy.

“Patients generally feel more comfortable and are willing to train longer when using VR. We receive videos from clients showing clear progress—like a patient with a shoulder injury struggling to raise their arm during conventional exercise, yet lifting it much higher during VR therapy without even realising it.”

VR therapy has already been shown to support recovery after spinal injuries, surgeries, or strokes. It is also used in psychotherapy for treating phobias, anxiety, depression, and eating disorders. VR is proving to be a powerful tool in therapy for patients with Alzheimer’s disease.

The World’s First VR Hydrogen Park

“Combining virtual reality with molecular hydrogen in healthcare inspired us to create the world’s first H₂ VR Park in Ostrava,” says David Maršálek.

“This will be a place for relaxation and enjoyment for children, adults, and seniors alike. Thanks to virtual reality, visitors will be able to ‘travel’ to the sea, mountains, or even experience skydiving—fulfilling dreams that might otherwise remain out of reach. All of this in one place, safely, and with the added benefits of molecular hydrogen.”

Thanks to the generous support of a local Ostrava investor, H₂ VR Park Ostrava will welcome its first visitors in September 2023. Following the innovative H₂ Bike, the H₂ VR Park is another world-class project based in H₂ City, symbolising Czech innovation on a global scale.

H2 Global Group merged with VR LIFE

H2 Global Group merged with VR LIFE

Molecular HydroGEN Investment Group, a subsidiary of the H2 Global Group, has invested CZK 15 million in VR LIFE, acquiring a 20% equity stake in the Czech company known for its cutting-edge medical virtual reality product, VR Vitalis. This strategic partnership follows the recent registration of a joint Czech patent and utility model for the world’s first therapy combining molecular hydrogen inhalation with immersive virtual reality.

“When I first met Dr Jana Trdá to present the idea of combining VR with hydrogen therapy, I didn’t expect rejection—in fact, I knew she was the one person in the Czech Republic with the expertise and vision to make it a reality,” recalls David Maršálek, President of H2 Global Group, of the collaboration’s beginnings in November 2022.
“Thanks to our patent expert, we successfully registered the patent and utility model by the end of June. This bridge investment is a natural next step, reflecting the strong synergy and proven results of our cooperation.”

Through its investment, H2 Global Group is supporting VR LIFE in further developing therapeutic VR environments and applications for rehabilitation, cognitive training, and mental health support.

“We see enormous potential in the combination of virtual reality and hydrogen,” says Květoslav Chytil, Vice President of Investments at H2 Global Group and now a supervisory board member at VR LIFE.
“Like H2 Global Group, VR LIFE is highly innovative. This partnership positions us at the heart of the company’s growth, with strong potential for return on investment.”

VR LIFE’s valuation has skyrocketed from CZK 10 million in 2022 to CZK 75 million in just six months.

“Our partnership is not just about product development—it’s about accelerating global market entry,” adds Martin Frais, Director of Molecular HydroGEN Investment Group. “We’re also seeing growing interest from investors keen to be part of this unique opportunity in the evolving field of health-tech.”

A Therapy Like No Other: VR + Molecular Hydrogen

The partnership is rooted in a patented therapy that combines exercise in virtual reality with 99.9% pure hydrogen inhalation. Hydrogen is delivered through a nasal cannula using generators from H2 Medical Technologies, a member of H2 Global Group.

“Inhaled molecular hydrogen significantly speeds up recovery from conditions like post-COVID syndrome and chronic inflammation,” explains Professor Shigeo Ohta, world-renowned Japanese scientist and Vice President for Science and Research at H2 Global Group.
“Hydrogen’s benefits in treating Alzheimer’s—where H2 Global Group also holds a patent—highlight the vast potential of this therapeutic pairing.”

Patients are immersed in a virtual Victorian greenhouse, designed to evoke the feeling of warm, moist air. As they follow visual cues—such as animated lungs that expand and contract—they synchronise their breathing, optimising hydrogen absorption.

“For standing therapy, we’ve introduced a hydrogen-filled tent that allows freedom of movement within the VR environment,” says David Maršálek. “We’re also preparing to launch home-based physical, rehabilitation and breathing exercises using this method.”
Jana Trdá, PhD, CEO of VR LIFE

VR as a Pathway to Health

In the VR environment, patients enter a fully immersive world, distancing themselves from external distractions. They follow guided exercises designed by a multidisciplinary team of physicians, physiotherapists, and occupational therapists, who also validate the therapeutic protocols.

VR Vitalis and its professional medical version, VR Vitalis Pro, are certified for use across the European Union. These tools support cognitive development, mobility, breathing, relaxation, and postural correction.

Already adopted by major institutions—Lázně Darkov, University Hospital Ostrava, Škoda Auto, and memory centres—the technology is proving effective both in therapy and employee well-being programmes.

“Since 2020, a multidisciplinary team from the Faculty of Medicine at Ostrava University and University Hospital Ostrava has developed VR modules for patients with nervous system and motor impairments,” explains Assoc. Prof. MUDr. Michal Filip, Ph.D., MBA, Head of the Centre for AI, VR and Telemedicine at the Faculty of Medicine, OSU, and neurosurgeon at Tomáš Baťa Regional Hospital in Zlín.
“Nationally supported projects confirm the potential of VR as a complementary therapy for patients of all ages.”

The initiative is backed by the Czech Technology Agency, CzechTrade, Vodafone Foundation, and other organisations. Meanwhile, VR LIFE is also developing Awake, a promising application for use in awake neurosurgical procedures.

H2 Global Group
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.